We use some essential cookies to make this website work.
We鈥檇 like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A reflection by Dr June Raine, Chief Executive of the Medicines and Healthcare products Regulatory Agency
This monoclonal antibody 鈥� the second to be authorised by the Medicines and Healthcare products Regulatory Agency 鈥� is for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
皇冠体育app antiviral was found to be safe and effective following a stringent review of the available evidence.
AWTTC joins the Innovative Licensing and Access Pathway as a permanent partner
Regulatory updates by the MHRA today on the COVID-19 booster vaccine programme for winter 2021 to 2022
皇冠体育app regulatory changes made by the MHRA today give further options for the deployment programme.
皇冠体育app Medicines and Healthcare products Regulatory Agency (MHRA) has today given approval for the first monoclonal antibody treatment for the prevention and treatment of COVID-19 in the UK.
First published during the 2019 to 2022 Johnson Conservative government
皇冠体育app UK regulator has confirmed the vaccine is safe and effective in this age group.
This follows a rigorous review of the safety, quality and effectiveness of the vaccine in this age group.
皇冠体育app vaccine has been approved after meeting the required safety, quality and effectiveness standards.
Change approved following detailed review of additional stability data
皇冠体育app MHRA is committed to speeding up access to innovative new medicines for patients.
Future vaccine modifications鈥痶hat respond to new variants of coronavirus to鈥痓e鈥痬ade available quickly鈥痶o UK recipients,鈥痺ithout compromising on safety, quality or effectiveness.鈥��
皇冠体育app Innovative Licensing and Access Pathway (ILAP) aims to reduce the time to market for innovative medicines
皇冠体育app Medicines and Healthcare products Regulatory Agency (MHRA) today, 1 January 2021, formally starts the Innovative Licensing and Access Pathway (ILAP).
MHRA Chief Executive Dr June Raine explains the process behind the Agency's approval of the Pfizer/BioNTech vaccine
MHRA has today given the first positive scientific opinion under the Early Access to Medicines Scheme (EAMS) for use of Gilead鈥檚 remdesivir.
Patients are urged to stop taking 5mg ulipristal acetate as soon as possible and contact a healthcare professional for advice on alternative treatments.
Paying for medicines licences, clinical trials and clinical investigations is changing from 1 April the Medicines and Healthcare products Regulatory Agency (MHRA) announced.
Don鈥檛 include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we鈥檇 like to know more about your visit today. .